样式: 排序: IF: - GO 导出 标记为已读
-
Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer’s Disease in Amnestic Mild Cognitive Impairment Subjects J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-19
Abstract Introduction Novel plasma biomarkers are promising for identifying Alzheimer’s disease (AD) pathological processes in vivo, but most currently employed assays have limitations precluding widespread use. Methods CSF and plasma samples were collected from seventy amnestic mild cognitive impairment (aMCI) subjects, stratified as A+ and A−. CSF Aβ40, Aβ42, p-tau181 and t-tau and plasma Aβ40, Aβ42
-
Association of Cognitive Reserve Indicator with Cognitive Decline and Structural Brain Differences in Middle and Older Age: Findings from the UK Biobank J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-19
Abstract Background Cognitive reserve (CR) contributes to preserving cognition when facing brain aging and damage. CR has been linked to dementia risk in late life. However, the association between CR and cognitive changes and brain imaging measures, especially in midlife, is unclear. Objective We aimed to explore the association of CR with cognitive decline and structural brain differences in middle
-
At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer’s Disease: Feasibility, Safety and Pharmacodynamic Impact J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-19 Frank G. Boess, M. A. Scelsi, T. Grimmer, R. J. Perry, M. Tonietto, G. Klein, C. Hofmann, M. Salami, J. Wojtowicz, C. J. Lansdall, C. Lane, G. A. Kerchner, J. Smith, R. S. Doody
-
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-19
Abstract Background Subjective hearing loss (SHL) refers to an individual’s self-assessment of their hearing loss. The association and underlying mechanisms between SHL and cognitive impairment still necessitate elucidation. Objectives To validate potential mechanisms between SHL and cognitive impairment. Design Cross-section. Setting Shanghai, China. Participants A total of 2369 individuals from communities
-
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-19 Haiyan Liu, J. Li, E. Ziegemeier, S. Adams, E. McDade, D. B. Clifford, Y. Cao, G. Wang, Y. Li, S. L. Mills, A. M. Santacruz, S. Belyew, J. D. Grill, B. J. Snider, C. J. Mummery, G. Surti, D. Hannequin, D. Wallon, S. B. Berman, I. Z. Jimenez-Velazquez, E. D. Roberson, C. H. van Dyck, L. S. Honig, R. Sanchez-Valle, W. S. Brooks, S. Gauthier, D. Galasko, C. L. Masters, J. Brosch, G.-Y. R. Hsiung, S. Jayadev
-
The Multi-domain Lifestyle Intervention for Cognitive Impairment in Community-Dwelling Older Adults in Hangzhou (The Heritage Study): Study Design and Protocol J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-19 Xin Xu, T. Pang, Y. Zhou, H. Zhang, A. Ma, C. Yuan, H. Chen, X. Wen, Q. Yang, X. Xu
-
Sex Difference in the Association between Prior Fracture and Subsequent Risk of Incident Dementia: A Longitudinal Cohort Study J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-13 D. Gao, W. Rong, C. Li, J. Liang, Y. Wang, Y. Pan, W. Zhang, Fanfan Zheng, Wuxiang Xie
-
Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of “Time Saved” J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-13 Samuel Dickson, A. Solomon, M. Kivipelto, T. Hartmann, A. M. J. van Hees, A. Brownlee, B. Haaland, C. H. Mallinckrodt, S. B. Hendrix
-
Usability of a Web-Based Registry for Preclinical Alzheimer’s Disease: Implications from a Cross-Sectional Online Survey J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-05 Kenichiro Sato, Y. Niimi, R. Ihara, K. Suzuki, A. Iwata, Takeshi Iwatsubo
-
Examining Demographic Factors, Psychosocial Wellbeing and Cardiovascular Health in Subjective Cognitive Decline in the Brain Health Registry Cohort J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-05 Rachana Tank, A. Diaz, M. T. Ashford, M. J. Miller, J. Eichenbaum, A. Aaronson, B. Landavazo, J. Neuhaus, M. W. Weiner, R. S. Mackin, J. Barnes, R. L. Nosheny
Background Subjective cognitive decline (SCD) is defined as an individual’s perception of sustained cognitive decline compared to their normal state while still performing within boundaries for normal functioning. Demographic, psychosocial and medical factors have been linked to age-related cognitive decline, and Alzheimer’s dementia (AD). However, their relation to risk for SCD remains unclear. This
-
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-05 J.-M. Pyun, M. J. Kang, S. J. Baek, K. Lee, Y. H. Park, SangYun Kim
-
Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-06 Y. Wang, D. Ren, J. S. Roberts, L. K. Tamres, J. H. Lingler
Background Growing evidence supports the clinical utility of amyloid PET, however, whether patients at risk for dementia use knowledge of their brain amyloid status to alter their health behaviors remains unclear. Objectives To explore the effect of amyloid PET results disclosure on self-reported health behaviors in patients with mild cognitive impairment. Design Self-reported health behaviors were
-
Prediction of Alzheimer’s Disease Based on 3D Genome Selected circRNA J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-06
Abstract Alzheimer’s disease (AD) is a neurodegenerative disease and there is by far no effective treatment for it, especially in its late stage. Circular RNAs (circRNAs), known as a class of non-coding RNAs are widely observed in eukaryotic transcriptomes, and are reported to play an important role in neurodegenerative diseases including AD. circRNAs usually act as microRNA (miRNA) inhibitors or «sponges»
-
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-06 M. N. Temedda, A. Garnier-Crussard, C. Mouchoux, Virginie Dauphinot
-
Female Reproductive Factors and Risk of Mild Cognitive Impairment and Dementia: The HUNT Study J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-05 Yehani Wedatilake, C. Myrstad, S. E. Tom, B. H. Strand, S. Bergh, G. Selbæk
Background More women are living with dementia than men worldwide and there is a need to investigate causes for this female preponderance. While reproductive factors have been investigated as risk factors, the results are conflicting. We aim to clarify this using a large cohort with a long observation time, adjusting for multiple health and lifestyle variables and encompassing a wider range of cognitive
-
Global Burden of Alzheimer’s Disease and Other Dementias Attributed to High Fasting Plasma Glucose from 1990 to 2019 J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-03-05 M. Wang, K. Huang, Yinzi Jin, Z.-J. Zheng
-
Longitudinal Impacts of Precision Greenness on Alzheimer’s Disease J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-16 S. C. Brown, W. W. Aitken, J. Lombard, A. Parrish, J. R. Dewald, R. Ma, S. Messinger, S. Liu, M. I. Nardi, T. Rundek, J. Szapocznik
-
Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer’s Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-15 Y. Guo, C.-C. Tan, M. S. Tan, L. Tan, W. Xu
-
Who Benefited Most from the Internet-Based Conversational Engagement RCT (I-CONECT)? Application of the Personalized Medicine Approach to a Behavioral Intervention Study J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-15 Chao-Yi Wu, K. Yu, S. E. Arnold, S. Das, H. H. Dodge
-
Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-10 Angela C. Bradshaw, J. Georges
The growing prevalence and burden of Alzheimer’s disease has catalysed huge investments in research on its causes, diagnosis, treatment and care. After many high-profile failures, recent clinical trials of anti-amyloid drugs have marked a turning point for the field, leading to the approval of the first disease-modifying therapies for Alzheimer’s disease by the FDA. It is now up to European regulators
-
Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-09 N. D. Prins, W. de Haan, A. Gardner, K. Blackburn, H.-M. Chu, J. E. Galvin, John J. Alam
-
Estimated Investment Need to Increase England’s Capacity to Diagnose Eligibility for an Alzheimer’s Treatment to G7 Average Capacity Levels J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-07 Soeren Mattke, Z. Shi, M. Hanson, S. Mitchell, C. Lynch, K. MacLean Kalonji, L. Lanman
-
Multiomics Blood-Based Biomarkers Predict Alzheimer’s Predementia with High Specificity in a Multicentric Cohort Study J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-06 B. Souchet, A. Michaïl, M. Heuillet, A. Dupuy-Gayral, E. Haudebourg, C. Pech, A. Berthemy, F. Autelitano, B. Billoir, K. Domoto-Reilly, C. Fowler, T. Grabowski, S. Jayadev, C. L. Masters, Jérôme Braudeau
-
A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-06 C. M. Erickson, J. Karlawish, J. D. Grill, K. Harkins, S. M. Landau, M. G. Rivera-Mindt, O. Okonkwo, R. C. Petersen, P. S. Aisen, M. W. Weiner, Emily A. Largent
-
24-Hour Blood Pressure Variability Via Ambulatory Monitoring and Risk for Probable Dementia in the SPRINT Trial J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-02-07
Abstract Background Blood pressure variability is an emerging risk factor for dementia, independent and oftentimes beyond mean blood pressure levels. Recent evidence from interventional cohorts with rigorously controlled mean blood pressure levels suggest blood pressure variability over months to years remains a risk for dementia, but no prior studies have investigated relationships with blood pressure
-
Fruit Intake and Alzheimer’s Disease: Results from Mendelian Randomization J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-31 Wan-Zhe Liao, X.-F. Zhu, Q. Xin, Y.-T. Mo, L.-L. Wang, X.-P. He, Xu-Guang Guo
-
Health Economic Considerations in the Deployment of an Alzheimer’s Prevention Therapy J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-30 Soeren Mattke, H. Jun, M. Hanson, S. Chu, J. H. Kordower, E. M. Reiman
-
Potential Implications of Slowing Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Estimates from Real-World Data J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-30 J. Chandler, N. Done, Urvi Desai, M. Georgieva, A. Gomez-Lievano, W. Ye, A. Zhao, D. Eid, A. Hilts, N. Kirson, T. Schilling
-
Polygenic Risk Score Reveals Genetic Heterogeneity of Alzheimer’s Disease between the Chinese and European Populations J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-30 F. Li, S. Xie, J. Cui, Y. Li, T. Li, Y. Wang, Jianping Jia
-
Vortioxetine Treatment for Depression in Patients with Prodromal vs Mild Alzheimer’s Disease: A Six-Month, Open-Label, Observational Study J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-30 Alessandro Padovani, S. Caratozzolo, A. Benussi, A. Galli, L. Rozzini, M. Cosseddu, R. Turrone, A. Pilotto
-
Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer’s Disease Risk: Evidence, Opportunities, and Challenges J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-30
Abstract Alzheimer’s disease and its comorbidities pose a heavy disease burden globally, and its treatment remains a major challenge. Identifying the protective and risk factors for Alzheimer’s disease, as well as its possible underlying molecular processes, can facilitate the development of interventions that can slow its progression. Observational studies and randomized controlled trials have provided
-
Impact of Differential Rates of Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Findings from a Longitudinal Cohort Analysis J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-30 J. Chandler, M. Georgieva, Urvi Desai, N. Done, A. Gomez-Lievano, W. Ye, A. Zhao, D. Eid, A. Hilts, N. Kirson, T. Schilling
-
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer’s Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-30
Abstract The Real-World Implementation, Deployment, and Validation of Early Detection Tools and Lifestyle Enhancement (AD-RIDDLE) project, recently launched with the support of the EU Innovative Health Initiative (IHI) public-private partnership and UK Research and Innovation (UKRI), aims to develop, test, and deploy a modular toolbox platform that can reduce existing barriers to the timely detection
-
A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-24 Wendy Luca, K. Foster, K. McClure, M. K. Ahlijanian, M. Jefson
-
Investigating the Impact of Tea Consumption on Cognitive Function and Exploring Tea-Genetic Interactions in Older Adults Aged 65–105 Years: Findings from the 2002–2018 CLHLS Data J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-24 L. Yu, M. Yang, K. X. Ye, C. Li, M. Zou, J. Wang, X. Yuan, D. Zheng, C. Sun, Y. Zhang, Q. Feng, A. B. Maier, L. Sun, L. Feng, Yanyu Wang, Huashuai Chen, Yi Zeng
-
Nanolithium, a New Treatment Approach to Alzheimer’s Disease: A Review of Existing Evidence and Clinical Perspectives J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-24
Abstract Lithium has been approved and used for several decades in the treatment of psychiatric disorders, and its potential effect in neurodegenerative diseases has been subject to increasing research interest in recent years. Nanolithium is a new experimental product using a novel drug-delivery technology (Aonys®), which optimizes its bioavailability while reducing its toxicity profile. Therapeutic
-
Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-23 Matthias Klee, V. T. E. Aho, P. May, A. Heintz-Buschart, Z. Landoulsi, S. R. Jónsdóttir, C. Pauly, L. Pavelka, L. Delacour, A. Kaysen, R. Krüger, P. Wilmes, A. K. Leist, Geeta Acharya, Gloria Aguayo, Myriam Alexandre, Muhammad Ali, Wim Ammerlann, Giuseppe Arena, Rudi Balling, Michele Bassis, Katy Beaumont, Regina Becker, Camille Bellora, Guy Berchem, Daniela Berg, Alexandre Bisdorff, Ibrahim Boussaad
-
Cognitive Training with Older Adults Using Smartphone and Web-Based Applications: A Scoping Review J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-23 A. F. Silva, Rui Miguel Silva, E. Murawska-Ciałowicz, G. Zurek, N. Danek, M. Cialowicz, J. Carvalho, F. M. Clemente
-
Roles of Baseline Intrinsic Capacity and its Subdomains on the Overall Efficacy of Multidomain Intervention in Promoting Healthy Aging among Community-Dwelling Older Adults: Analysis from a Nationwide Cluster-Randomized Controlled Trial J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-23 C.-K. Liang, W.-J. Lee, M.-Y. Chou, A.-C. Hwang, C.-S. Lin, L.-N. Peng, F.-Y. Hsiao, C.-H. Loh, Liang-Kung Chen
-
Who Benefited the Most? Effectiveness of a Lifestyle Intervention Against Cognitive Decline in Older Women and Men – Secondary Analysis of the AgeWell.de-trial J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-15 Felix G. Wittmann, A. Pabst, A. Zülke, M. Luppa, I. Blotenberg, M. I. Cardona, A. Bauer, S. Fuchs, I. Zöllinger, L. Sanftenberg, C. Brettschneider, J. Döhring, L. Lunden, D. Czock, B. Wiese, J. R. Thyrian, W. Hoffmann, T. Frese, J. Gensichen, H.-H. König, H. Kaduszkiewicz, S. G. Riedel-Heller
Introduction Differences between women and men matter in the prevalence and risk factors of dementia. We aimed to examine potential sex differences regarding the effectiveness by running a secondary analysis of the AgeWell.de trial, a cluster-randomized multicenter multi-domain lifestyle intervention to reduce cognitive decline. Methods Intention-to-treat analyses of women (n=433) and men (n=386) aged
-
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer’s Disease in Cognitively Unimpaired Older Adults J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-15 Mario A. Parra, Y. Gazes, C. Habeck, Y. Stern
-
Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer’s Disease J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-15 A. C. Macedo, D. F. P. A. Durço, C. Tissot, J. Therriault, A. O. Vilela de Faria, É. Aumont, S. Servaes, N. Rahmouni, J. Fernandez-Arias, Y.-T. Wang, F. Z. Lussier, A. Bieger, E. R. Zimmer, T. A. Pascoal, S. Gauthier, Pedro Rosa-Neto
-
Cost-Effectiveness of Prevention for People at Risk for Dementia: A Scoping Review and Qualitative Synthesis J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-15
Abstract Dementia is from an economic perspective a main challenge for economies worldwide because of increasing costs. Since there is no cure in sight, prevention seems the most promising approach for reducing health care cost due to Dementia. On the contrary, approximately 40% of dementias is attributable to modifiable risk factors and first studies showed that multidomain interventions may be effective
-
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer’s Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-15 G. García-Lluch, Juan Pardo Albiach, L. Moreno, C. Peña-Bautista, M. Baquero, Consuelo Cháfer-Pericás
-
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer’s Disease: A Systematic Review and Meta-Analysis J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-15
Abstract Background Alzheimer’s disease (AD) is a progressive neurodegenerative illness that leads to impairment of cognitive functions and memory loss. Even though there is a plethora of research reporting the abnormal regulation of VEGF expression in AD pathogenesis, whether the CSF and serum VEGF are increased in AD is an open question yet. In this study, the association of CSF and serum VEGF concentrations
-
Ethical Considerations at the Intersection of Social Media and Dementia Prevention Research J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 V. Hrincu, G. Zaleski, J. M. Robillard
-
The MAPP Room Memory Test: Examining Contextual Memory Using a Novel Computerized Test in Cognitively-Unimpaired Individuals with Autosomal Dominant Alzheimer’s Disease J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 A. Giudicessi, P. A. Aduen, J. T. Fox-Fuller, J. E. Martinez, L. A. Gonzalez, C. Vila-Castelar, A. Baena, C. Pluim McDowell, A. Cronin-Golomb, F. Lopera, Yakeel T. Quiroz
-
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer’s Disease or Amnesic Mild Cognitive Impairment J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 J.-Y. Wang, J.-Y. Qin, J.-Y. Ye, W.-T. Li, M.-Q.-Z. Tong, Hui Ouyang, Fengxia Yan
-
Association of Multi-Domain Factors with Cognition in the UK Biobank Study J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 W. Y. Tan, C. A. Hargreaves, N. Kandiah, Saima Hilal
-
Integrated Bioinformatic Analysis and Validation Identifies Immune Microenvironment-Related Potential Biomarkers in Alzheimer’s Disease J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 F. Yang, N. Zhang, G.-Y. Ou, Shu-wen Xu
-
Alzheimer’s Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08
Abstract Background Alzheimer’s disease (AD) biomarker tests can be ordered as part of the diagnostic workup of patients with mild cognitive impairment (MCI). Little is known about how patients with MCI and their care partners decide whether to pursue testing. Objective To examine factors that influence AD biomarker testing decisions among patients with MCI and their care partners. Design We performed
-
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer’s Disease J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 Marc Cantillon, N. Andreasen, N. Prins
-
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 L. Hao, M. Shi, J. Ma, S. Shao, Y. Yuan, J. Liu, Z. Yu, Zhenqiang Zhang, Christian Hölscher, Zijuan Zhang
-
The MAPP Room Memory Test: Examining Contextual Memory Using a Novel Computerized Test in Cognitively-Unimpaired Individuals with Autosomal Dominant Alzheimer’s Disease J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 A. Giudicessi, P. A. Aduen, J. T. Fox-Fuller, J. E. Martinez, L. A. Gonzalez, C. Vila-Castelar, A. Baena, C. Pluim McDowell, A. Cronin-Golomb, F. Lopera, Yakeel T. Quiroz
-
Personalized Computational Causal Modeling of the Alzheimer Disease Biomarker Cascade J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2024-01-08 Jeffrey R. Petrella, J. Jiang, K. Sreeram, S. Dalziel, P. M. Doraiswamy, W. Hao
-
Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2023-10-24 Ying Liu, H. Jun, A. Becker, C. Wallick, S. Mattke
-
Opportunities for Cellular Rejuvenation in Alzheimer’s Disease: How Epigenetic Reprogramming and Chaperone-Mediated Autophagy Are Enabling Next Generation Therapeutic Approaches J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2023-10-24 Sharon Rosenzweig-Lipson
Age remains the largest risk factor in the development of neurodegenerative diseases such as Alzheimer’s disease (AD). Numerous cellular hallmarks of aging contribute to the advancement of the pathologies associated with neurodegenerative disease. Not all cellular hallmarks of aging are independent and several fall into the broader category of cellular rejuvenation, which captures returning cells to
-
Fibrin-Targeting Immunotherapy for Dementia J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2023-10-24 A. B. Kantor, K. Akassoglou, Jeffrey B. Stavenhagen
-
Translating the Biology of Aging into New Therapeutics for Alzheimer’s Disease: Senolytics J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2023-10-24 M. Riessland, Miranda E. Orr
-
Geroscience and Alzheimer’s Disease Drug Development J. Prev. Alzheimers Dis. (IF 6.4) Pub Date : 2023-10-24 Jeffrey Cummings, A. M. Leisgang Osse, J. Kinney